CARL ZEISS MEDITEC AG - BR (AFX.DE) Fundamental Analysis & Valuation

FRA:AFX • DE0005313704

25.04 EUR
-0.34 (-1.34%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This AFX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, AFX scores 5 out of 10 in our fundamental rating. AFX was compared to 63 industry peers in the Health Care Equipment & Supplies industry. AFX has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on AFX.


Dividend Valuation Growth Profitability Health

4

1. AFX.DE Profitability Analysis

1.1 Basic Checks

  • AFX had positive earnings in the past year.
  • In the past year AFX had a positive cash flow from operations.
  • Each year in the past 5 years AFX has been profitable.
  • Each year in the past 5 years AFX had a positive operating cash flow.
AFX.DE Yearly Net Income VS EBIT VS OCF VS FCFAFX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • With a decent Return On Assets value of 4.15%, AFX is doing good in the industry, outperforming 63.49% of the companies in the same industry.
  • AFX has a Return On Equity of 6.67%. This is comparable to the rest of the industry: AFX outperforms 49.21% of its industry peers.
  • The Return On Invested Capital of AFX (5.79%) is comparable to the rest of the industry.
  • AFX had an Average Return On Invested Capital over the past 3 years of 7.11%. This is below the industry average of 9.88%.
Industry RankSector Rank
ROA 4.15%
ROE 6.67%
ROIC 5.79%
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
AFX.DE Yearly ROA, ROE, ROICAFX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10

1.3 Margins

  • The Profit Margin of AFX (6.34%) is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of AFX has declined.
  • The Operating Margin of AFX (10.03%) is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of AFX has declined.
  • The Gross Margin of AFX (52.76%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
Industry RankSector Rank
OM 10.03%
PM (TTM) 6.34%
GM 52.76%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
AFX.DE Yearly Profit, Operating, Gross MarginsAFX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AFX.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AFX is creating some value.
  • AFX has about the same amout of shares outstanding than it did 1 year ago.
  • AFX has less shares outstanding than it did 5 years ago.
  • AFX has a better debt/assets ratio than last year.
AFX.DE Yearly Shares OutstandingAFX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AFX.DE Yearly Total Debt VS Total AssetsAFX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • AFX has an Altman-Z score of 2.84. This is not the best score and indicates that AFX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of AFX (2.84) is comparable to the rest of the industry.
  • The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.41, AFX is in line with its industry, outperforming 57.14% of the companies in the same industry.
  • AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
  • AFX has a Debt to Equity ratio of 0.27. This is in the better half of the industry: AFX outperforms 61.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 4.41
Altman-Z 2.84
ROIC/WACC0.86
WACC6.73%
AFX.DE Yearly LT Debt VS Equity VS FCFAFX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 2.35 indicates that AFX has no problem at all paying its short term obligations.
  • AFX has a Current ratio of 2.35. This is in the better half of the industry: AFX outperforms 71.43% of its industry peers.
  • A Quick Ratio of 1.44 indicates that AFX should not have too much problems paying its short term obligations.
  • The Quick ratio of AFX (1.44) is better than 73.02% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.44
AFX.DE Yearly Current Assets VS Current LiabilitesAFX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AFX.DE Growth Analysis

3.1 Past

  • AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.51%.
  • Measured over the past 5 years, AFX shows a small growth in Earnings Per Share. The EPS has been growing by 3.28% on average per year.
  • The Revenue has been growing slightly by 5.89% in the past year.
  • Measured over the past years, AFX shows a quite strong growth in Revenue. The Revenue has been growing by 10.78% on average per year.
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%

3.2 Future

  • AFX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.66% yearly.
  • Based on estimates for the next years, AFX will show a small growth in Revenue. The Revenue will grow by 4.97% on average per year.
EPS Next Y20.35%
EPS Next 2Y21.07%
EPS Next 3Y21.31%
EPS Next 5Y16.66%
Revenue Next Year2.7%
Revenue Next 2Y4.1%
Revenue Next 3Y4.4%
Revenue Next 5Y4.97%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AFX.DE Yearly Revenue VS EstimatesAFX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
AFX.DE Yearly EPS VS EstimatesAFX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

7

4. AFX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 17.15, which indicates a rather expensive current valuation of AFX.
  • Based on the Price/Earnings ratio, AFX is valued cheaper than 84.13% of the companies in the same industry.
  • AFX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.29.
  • Based on the Price/Forward Earnings ratio of 10.61, the valuation of AFX can be described as reasonable.
  • AFX's Price/Forward Earnings ratio is rather cheap when compared to the industry. AFX is cheaper than 87.30% of the companies in the same industry.
  • AFX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.57.
Industry RankSector Rank
PE 17.15
Fwd PE 10.61
AFX.DE Price Earnings VS Forward Price EarningsAFX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AFX is valued cheaper than 88.89% of the companies in the same industry.
  • 84.13% of the companies in the same industry are more expensive than AFX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 16.81
EV/EBITDA 7.95
AFX.DE Per share dataAFX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AFX's earnings are expected to grow with 21.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.84
PEG (5Y)5.23
EPS Next 2Y21.07%
EPS Next 3Y21.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. AFX.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.02%, AFX has a reasonable but not impressive dividend return.
  • In the last 3 months the price of AFX has falen by -42.36%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • AFX's Dividend Yield is a higher than the industry average which is at 1.06.
  • AFX's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 2.02%

5.2 History

  • The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
AFX.DE Yearly Dividends per shareAFX.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 37.19% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
DP37.19%
EPS Next 2Y21.07%
EPS Next 3Y21.31%
AFX.DE Yearly Income VS Free CF VS DividendAFX.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M
AFX.DE Dividend Payout.AFX.DE Dividend Payout, showing the Payout Ratio.AFX.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

AFX.DE Fundamentals: All Metrics, Ratios and Statistics

CARL ZEISS MEDITEC AG - BR

FRA:AFX (3/6/2026, 7:00:00 PM)

25.04

-0.34 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)05-11
Inst Owners25.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.24B
Revenue(TTM)2.20B
Net Income(TTM)141.22M
Analysts66.96
Price Target37.68 (50.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.02%
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-24.3%
PT rev (3m)-32.18%
EPS NQ rev (1m)-17.33%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-6.39%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.47%
Revenue NY rev (3m)-2.15%
Valuation
Industry RankSector Rank
PE 17.15
Fwd PE 10.61
P/S 1.01
P/FCF 16.81
P/OCF 10.67
P/B 1.06
P/tB 4.63
EV/EBITDA 7.95
EPS(TTM)1.46
EY5.83%
EPS(NY)2.36
Fwd EY9.42%
FCF(TTM)1.49
FCFY5.95%
OCF(TTM)2.35
OCFY9.37%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)0.84
PEG (5Y)5.23
Graham Number27.88
Profitability
Industry RankSector Rank
ROA 4.15%
ROE 6.67%
ROCE 7.81%
ROIC 5.79%
ROICexc 5.89%
ROICexgc 14.08%
OM 10.03%
PM (TTM) 6.34%
GM 52.76%
FCFM 5.98%
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 4.41
Debt/EBITDA 1.61
Cap/Depr 60.61%
Cap/Sales 3.44%
Interest Coverage 10.38
Cash Conversion 60%
Profit Quality 94.37%
Current Ratio 2.35
Quick Ratio 1.44
Altman-Z 2.84
F-Score6
WACC6.73%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
EPS Next Y20.35%
EPS Next 2Y21.07%
EPS Next 3Y21.31%
EPS Next 5Y16.66%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
Revenue Next Year2.7%
Revenue Next 2Y4.1%
Revenue Next 3Y4.4%
Revenue Next 5Y4.97%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year51.32%
EBIT Next 3Y23.17%
EBIT Next 5Y16.12%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%

CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ

What is the fundamental rating for AFX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.


What is the valuation status of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?

ChartMill assigns a valuation rating of 7 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Undervalued.


Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?

CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.


What are the PE and PB ratios of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?

The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 17.15 and the Price/Book (PB) ratio is 1.06.


Is the dividend of CARL ZEISS MEDITEC AG - BR sustainable?

The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 4 / 10 and the dividend payout ratio is 37.19%.